AbbVie Issues Inaugural Full-Year Outlook for 2013

              AbbVie Issues Inaugural Full-Year Outlook for 2013

  PR Newswire

  NORTH CHICAGO, Illinois, Jan. 30, 2013

-- HUMIRA delivers 9th year of double-digit growth in 2012; forecasting low
double-digit growth in 2013

-- Advances 11 Phase III programs; HCV Phase III trials underway and on track
for early 2015 launch

-- Provides full-year 2013 adjusted EPS guidance of $3.03 to $3.13 ($2.66 to
$2.76 on a GAAP basis)

NORTH CHICAGO, Illinois, Jan. 30, 2013 /PRNewswire/ -- AbbVie today confirmed
it delivered strong sales growth with its marketed pharmaceutical products in
2012.  The proprietary pharmaceutical segment of Abbott, representing the
majority of AbbVie's revenue, grew more than 8 percent globally on an
operational basis, excluding a nearly 3 percent negative impact from foreign
exchange.   

Performance was driven by solid double-digit growth from both HUMIRA and
AndroGel and continued growth from the company's portfolio of market-leading
therapies, including Creon and Synthroid.   

Additionally, AbbVie is issuing adjusted earnings-per-share guidance for the
full-year 2013 of $3.03 to $3.13, or $2.66 to $2.76 on a Generally Accepted
Accounting Principles (GAAP) basis.  The company's 2013 adjusted
earnings-per-share guidance excludes $0.37 per share of non-cash intangible
amortization expense and specified items, primarily associated with certain
separation-related costs and previously announced ongoing restructuring
activities.

"AbbVie's portfolio of marketed products delivered solid growth in 2012,
positioning us well for healthy performance in our first year as an
independent company," said Richard A. Gonzalez, chairman and chief executive
officer, AbbVie.  "In 2013, we expect to deliver on AbbVie's key priorities of
driving continued strong growth of HUMIRA, maximizing our specialty product
portfolio, advancing our promising pipeline including our late-stage HCV
program, and delivering returns to shareholders through our strong dividend."

Pipeline and Regulatory Milestones

In addition to strong sales growth, in 2012 AbbVie continued to execute on its
regulatory and clinical objectives.  This includes securing approvals for four
new HUMIRA indications; the addition of two promising mid-stage compounds,
including a next-generation JAK1 inhibitor and a novel therapy for acute
kidney injury; and the advancement of key development programs, including the
start of Phase III studies for our interferon-free Hepatitis C (HCV)
combination and elagolix.

AbbVie expects long-term growth will be fueled by a compelling pipeline of
therapies in development to address medical conditions with high unmet need. 
The company is focused on advancing a number of Phase III programs, including:
an interferon-free oral combination for HCV; daclizumab for relapsing
remitting multiple sclerosis (in partnership with Biogen); elagolix for
endometriosis; elotuzumab for multiple myeloma (in partnership with Bristol
Myers Squibb); and several new indications for HUMIRA.

In 2013, the company expects to initiate several Phase III programs including
atrasentan for diabetic kidney disease and ABT-199 in chronic lymphocytic
leukemia (CLL).  Additionally, AbbVie is planning Phase IIB starts for:
elagolix in uterine fibroids; our partnered JAK1 inhibitor (GLPG0634) for
rheumatoid arthritis (RA); BT-061 for RA; and ABT-719 for acute kidney injury
associated with major cardiac and other surgeries.  Finally, in 2013, the
company intends to present data from a number of key development programs,
including our rapidly advancing HCV program, oncology, renal disease,
immunology and Alzheimer's disease.

Management to Discuss Company Performance and Outlook on Investor Call Today

AbbVie will host an investor conference call today at 8 a.m. Central time to
discuss our fourth-quarter and full-year 2012 highlights and 2013 outlook.
Participating on the call will be Rick Gonzalez, chairman and chief executive
officer; Bill Chase, executive vice president and chief financial officer;
Laura Schumacher, executive vice president of business development, external
affairs and general counsel; John Leonard, senior vice president and chief
scientific officer; and Larry Peepo, vice president of investor relations. The
call will be webcast through AbbVie's Investor Relations website at
www.abbvieinvestor.com . An archived edition of the call will be available
after 11 a.m. Central time.

Key Product Performance:

The following is a summary of fourth-quarter 2012 sales for select AbbVie
products.

                                                       % Change vs. 4Q11
                     Sales ($ in
                      millions)                       Int'l                  Total
                 U.S.   Int'l  Total   U.S.   Operational  Reported  Operational  Reported
HUMIRA           1,413  1,268  2,681    31.1         17.9      15.2         24.5      23.1
TRILIPIX/TriCor    202     --    202  (50.7)          n/a       n/a       (50.7)    (50.7)
AndroGel           364     --    364    40.5          n/a       n/a         40.5      40.5
Kaletra             83    167    250  (17.0)        (9.4)    (11.4)       (12.1)    (13.4)
Lupron             155     56    211    11.3       (17.4)    (18.1)          1.8       1.6
Niaspan            277     --    277     7.4          n/a       n/a          7.4       7.4
Synthroid          168     --    168    24.9          n/a       n/a         24.9      24.9
Creon              105     --    105     3.9          n/a       n/a          3.9       3.9

The following is a summary of twelve-month 2012 sales for select AbbVie
products.

                                                      % Change vs. 12M11
                    Sales ($ in
                     millions)                       Int'l                  Total
                U.S.   Int'l  Total   U.S.   Operational  Reported  Operational  Reported
HUMIRA          4,376  4,889  9,265    27.7         15.4       8.5         20.7      16.8
TRILIPIX/TriCor 1,098     --  1,098  (19.9)          n/a       n/a       (19.9)    (19.9)
AndroGel        1,152     --  1,152    31.7          n/a       n/a         31.7      31.7
Kaletra           280    733  1,013  (14.1)        (7.6)    (13.2)        (9.4)    (13.4)
Lupron            569    231    800     5.4       (10.5)    (14.4)          0.1     (1.2)
Niaspan           911     --    911   (6.7)          n/a       n/a        (6.7)     (6.7)
Synthroid         551     --    551     5.7          n/a       n/a          5.7       5.7
Creon             353     --    353     6.5          n/a       n/a          6.5       6.5

Note:  "Operational" growth reflects percentage change over the prior year
excluding the impact of exchange rates.

About AbbVie AbbVie is a global, research-based biopharmaceutical company
formed in 2013 following separation from Abbott.  With its 125-year history,
the company's mission is to use its expertise, dedicated people and unique
approach to innovation to develop and market advanced therapies that address
some of the world's most complex and serious diseases.  In 2013, AbbVie
employs approximately 21,000 people worldwide and markets medicines in more
than 170 countries.  For further information on the company and its people,
portfolio and commitments, please visit www.abbvie.com . Follow @abbvie on
Twitter or view careers on our Facebook  or LinkedIn page.

Forward-Looking Statements Some statements in this news release may be
forward-looking statements for purposes of the Private Securities Litigation
Reform Act of 1995. AbbVie cautions that these forward-looking statements are
subject to risks and uncertainties that may cause actual results to differ
materially from those indicated in the forward-looking statements.  Economic,
competitive, governmental, technological and other factors that may affect
AbbVie's operations are discussed in the "Risk Factors" section of the
Information Statement attached to our Form 10 Registration Statement, which
has been filed with the SEC, and are incorporated by reference.  AbbVie
undertakes no obligation to release publicly any revisions to forward-looking
statements as a result of subsequent events or developments, except as
required by law.

Website: http://www.abbvie.com
Contact: Media, Jennifer Smoter, +1-847-935-8865, or Greg Miley,
+1-847-938-4898, or Adelle Infante, +1-847-938-8745, or Investors, Larry
Peepo, +1-847-935-6722, or, Liz Shea, +1-847-935-2211